Lakewood-Amedex Biotherapeutics Inc. reported operational continuity alongside severe liquidity shortfalls in its latest quarter ending March 31, 2026. The company focuses on developing Nu-3, targeting diabetic foot ulcers, an area with significant unmet clinical need but intense competition and regulatory complexity. Recent board appointment of seasoned biotech executive Dr. Joseph Tucker potentially strengthens governance and capital-raising capabilities. However, constrained current assets relative to liabilities underscore the critical need for funding to sustain development activities.